BOSTON, June 7, 2021: Morgan Lewis represented Cyclerion Therapeutics Inc. in a licensing agreement with Akebia Therapeutics Inc. for the development and commercialization of praliciguat, an oral soluble guanylate cyclase (sGC) stimulator.
Cyclerion is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Akebia is a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
Morgan Lewis life sciences transactions partner Suzanne Filippi and associate Andrew Haupt represented Cyclerion.